Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Accro Bioscience logo — company profile

Accro Bioscience

Founded 2016 1 employees Series B Total: $50.00M Biotechnology

General Information

Company Name Accro Bioscience
Founded Year 2016
Employees 1
Industries Biotechnology
Funding Stage Series B
Social

Get notified when Accro Bioscience moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Accro Bioscience

Accro Bioscience, founded in 2016, is a clinical-stage biotech company specializing in the molecular mechanisms of regulated cell death and related pathogenesis in human diseases. The company recently received a significant boost with a $50.00M Series B investment on 04 January 2022, attracting attention from prominent investors including Morningside Ventures, Shenzhen Capital Group, GF Xinde, Oriza Holdings, South China VC, and Hongtai Capital Holdings. Their focus on biotechnology places them at the forefront of medical innovation, making them an attractive prospect for venture capital investment.

Taxonomy: biotech, clinical-stage company, molecular mechanisms, regulated cell death, human diseases, clinical research, biopharmaceuticals, drug development, scientific research, biomedical innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 6
Investor Investor Investor Investor Investor Investor
04 Jan 2022

Accro Bioscience Alternatives & Competitors

Accro Bioscience vs
Northern Alberta Clinical Trials and Research Centre (NACTRC)
Northern Alberta Clinical Trials and Research Centre (NACTRC) Canada

Have questions about clinical research? We're here to help.

4 employees
Health Care
Accro Bioscience vs
INTEGRIUM LTD
INTEGRIUM LTD United States

We are entrusted with advancing the medical treatment of humankind.

1 employees
Accro Bioscience vs
Gen1 Research
Gen1 Research United States

Better care. It's necessary, and it's possible.

3 employees
Biotechnology, Health Care

FAQ About Accro Bioscience

Accro Bioscience is a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases.
Accro Bioscience was founded in 2016.
Accro Bioscience operates in the following industries: Biotechnology.
Accro Bioscience has approximately 1 employees.
Accro Bioscience has completed 1 funding round, raising a total of $50.00M. The latest funding stage is Series B.
Top alternatives and competitors to Accro Bioscience include Northern Alberta Clinical Trials and Research Centre (NACTRC), INTEGRIUM LTD, Gen1 Research, Clintract Clinical Research, Inc., Epsilon Ege CRO. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Accro Bioscience and Northern Alberta Clinical Trials and Research Centre (NACTRC) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Accro Bioscience and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy